Silence Therapeutics (NASDAQ:SLN) Given New $4.00 Price Target at The Goldman Sachs Group

Silence Therapeutics (NASDAQ:SLN - Free Report) had its target price decreased by The Goldman Sachs Group from $6.00 to $4.00 in a research note published on Tuesday morning,Benzinga reports. The Goldman Sachs Group currently has a sell rating on the stock.

SLN has been the subject of a number of other research reports. HC Wainwright reissued a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, January 29th. BMO Capital Markets reissued an "outperform" rating on shares of Silence Therapeutics in a research report on Monday, December 2nd. Chardan Capital restated a "buy" rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research report on Tuesday, December 10th. Finally, William Blair reaffirmed an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.67.

Silence Therapeutics Stock Performance

SLN stock traded up $0.11 during trading on Tuesday, hitting $4.85. 197,333 shares of the company traded hands, compared to its average volume of 307,544. The company has a 50-day moving average of $5.44 and a 200-day moving average of $11.48. Silence Therapeutics has a 1 year low of $4.06 and a 1 year high of $27.72. The firm has a market capitalization of $145.16 million, a PE ratio of -3.09 and a beta of 1.08.

Remove Ads

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SLN. Redmile Group LLC raised its stake in Silence Therapeutics by 26.3% in the fourth quarter. Redmile Group LLC now owns 2,399,317 shares of the company's stock worth $16,507,000 after buying an additional 500,000 shares in the last quarter. Janus Henderson Group PLC grew its holdings in shares of Silence Therapeutics by 32.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company's stock worth $19,798,000 after acquiring an additional 268,250 shares during the period. Nantahala Capital Management LLC raised its position in shares of Silence Therapeutics by 424.8% in the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock worth $7,222,000 after acquiring an additional 849,676 shares in the last quarter. Eventide Asset Management LLC bought a new position in shares of Silence Therapeutics in the 3rd quarter worth approximately $11,635,000. Finally, Point72 Asset Management L.P. lifted its stake in shares of Silence Therapeutics by 35.3% in the 4th quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company's stock valued at $4,356,000 after purchasing an additional 165,300 shares during the period. 98.73% of the stock is owned by hedge funds and other institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.